David M Peereboom1, Conleth Murphy, Manmeet S Ahluwalia, Alison Conlin, April Eichler, Catherine Van Poznak, Joseph Baar, Paul Elson, Andrew D Seidman. 1. Cleveland Clinic Lerner College of Medicine, Case Western Reserve University (D.M.P., M.S.A.); The Rose Ella Burkhardt Brain Tumor and NeuroOncology Center, Neurological Institute, Cleveland Clinic (D.M.P., M.S.A.); Taussig Cancer Institute, Cleveland Clinic (D.M.P., M.S.A., P.E.); Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio(P.E.); Memorial Sloan-Kettering Cancer Center, New York, New York(C.M., A.C., A.D.S.); Massachusetts General Hospital, Boston, Massachusetts(A.E.); Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan(C.V.P.); Seidman Cancer Center of University Hospitals, Case Medical Center, Cleveland, Ohio(J.B.).
Abstract
BACKGROUND: For patients with progressive breast cancer brain metastasis (BCBM) after whole brain radiotherapy (WBRT), few options exist. Patupilone is an epothilone that crosses the blood-brain barrier. We hypothesized that patupilone would produce a 35% 3-month CNS progression-free survival in women with BCBM after WBRT. METHODS: This multicenter phase II trial included 2 cohorts. Group A included women with progressive BCBM after WBRT. Group B was an exploratory cohort of patients with either leptomeningeal metastases or untreated brain metastases. The primary goal was to observe a 35% 3-month CNS progression-free survival in Group A. The sample size was 45 for Group A and 10 for Group B. Patients received patupilone 10 mg/m(2) once every 3 weeks until progression. Responses were scored according to the Macdonald criteria. RESULTS: Fifty-five patients (45 in Group A, 10 in Group B) enrolled. In Group A, the 3-month CNS progression-free survival was 27%, the median overall survival was 12.7 months, and the overall response rate was 9%. In Group B, which enrolled 5 patients with leptomeningeal disease and 5 with no prior WBRT, no responses occurred and 8 patients had CNS progression before 3 months. Systemic responses occurred in 15% of patients, including a complete response in liver metastases. Diarrhea occurred in 87% of patients; 25% had grade 3 and 4 adverse events. CONCLUSIONS: Patupilone in patients with BCBM did not meet the efficacy criteria and had significant gastrointestinal toxicity. Further study of brain-penetrant agents is warranted for patients with CNS metastases from breast cancer.
BACKGROUND: For patients with progressive breast cancer brain metastasis (BCBM) after whole brain radiotherapy (WBRT), few options exist. Patupilone is an epothilone that crosses the blood-brain barrier. We hypothesized that patupilone would produce a 35% 3-month CNS progression-free survival in women with BCBM after WBRT. METHODS: This multicenter phase II trial included 2 cohorts. Group A included women with progressive BCBM after WBRT. Group B was an exploratory cohort of patients with either leptomeningeal metastases or untreated brain metastases. The primary goal was to observe a 35% 3-month CNS progression-free survival in Group A. The sample size was 45 for Group A and 10 for Group B. Patients received patupilone 10 mg/m(2) once every 3 weeks until progression. Responses were scored according to the Macdonald criteria. RESULTS: Fifty-five patients (45 in Group A, 10 in Group B) enrolled. In Group A, the 3-month CNS progression-free survival was 27%, the median overall survival was 12.7 months, and the overall response rate was 9%. In Group B, which enrolled 5 patients with leptomeningeal disease and 5 with no prior WBRT, no responses occurred and 8 patients had CNS progression before 3 months. Systemic responses occurred in 15% of patients, including a complete response in liver metastases. Diarrhea occurred in 87% of patients; 25% had grade 3 and 4 adverse events. CONCLUSIONS:Patupilone in patients with BCBM did not meet the efficacy criteria and had significant gastrointestinal toxicity. Further study of brain-penetrant agents is warranted for patients with CNS metastases from breast cancer.
Entities:
Keywords:
brain metastases; breast cancer; chemotherapy; epothilone; patupilone
Authors: K N Chi; E Beardsley; B J Eigl; P Venner; S J Hotte; E Winquist; Y-J Ko; S S Sridhar; D Weber; F Saad Journal: Ann Oncol Date: 2011-07-16 Impact factor: 32.976
Authors: Rachel A Freedman; Elizabeth Bullitt; Lixian Sun; Rebecca Gelman; Gordon Harris; Jennifer A Ligibel; Ian E Krop; Ann H Partridge; Emily Eisenberg; Eric P Winer; Nancy U Lin Journal: Clin Breast Cancer Date: 2011-06-22 Impact factor: 3.225
Authors: Fabio M Iwamoto; Antonio M Omuro; Jeffrey J Raizer; Craig P Nolan; Adília Hormigo; Andrew B Lassman; Igor T Gavrilovic; Lauren E Abrey Journal: J Neurooncol Date: 2007-11-07 Impact factor: 4.130
Authors: Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531
Authors: Debu Tripathy; Sara M Tolaney; Andrew D Seidman; Carey K Anders; Nuhad Ibrahim; Hope S Rugo; Chris Twelves; Veronique Dieras; Volkmar Müller; Mary Tagliaferri; Alison L Hannah; Javier Cortés Journal: Future Oncol Date: 2019-05-10 Impact factor: 3.404
Authors: Yang Deng; Fan Yang; Emiliano Cocco; Eric Song; Junwei Zhang; Jiajia Cui; Muneeb Mohideen; Stefania Bellone; Alessandro D Santin; W Mark Saltzman Journal: Proc Natl Acad Sci U S A Date: 2016-09-23 Impact factor: 11.205
Authors: Lakshmi Nayak; Lisa M DeAngelis; H Ian Robins; Ramaswamy Govindan; Shirish Gadgeel; Karen Kelly; James R Rigas; David M Peereboom; Steven S Rosenfeld; Alona Muzikansky; Ming Zheng; Patrick Urban; Lauren E Abrey; Antonio Omuro; Patrick Y Wen Journal: Cancer Date: 2015-08-26 Impact factor: 6.860